Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma". by Voruz, S. et al.
Comment on “MEK inhibition with trametinib and
tyrosine kinase inhibition with imatinib in multifocal
histiocytic sarcoma”
We would like to follow up on the above-mentioned
paper1 to complete the history of our patient following
publication of the case.
After he progressed under imatinib treatment, as
already planned and mentioned in the paper, the patient
started a 6th line of therapy with nivolumab in June 2017,
16 months after the initial diagnosis. He had a good per-
formance status Eastern Cooperative Oncology Group
(ECOG 1) and no specific complaint apart from occasion-
al abdominal pain and grade 1 fatigue. Programmed
death-ligand 1 (PD-L1) expression in the initial diagnostic
tissue sample was heterogeneous in 15-20% of the
tumor. Because of the lack of any treatment guidelines,
our decision was based on the overexpression of the pro-
grammed death 1 (PD1)-PDL1 axis. PD-L1 expression is
frequently found in histiocytic tumors,2 and the rate of
clinical response reached up to 50% in a sarcoma study
on 38 patients.3 After three doses of nivolumab 3mg/kg
every other week, progressive disease was documented
on positron emission tomography–computed tomogra-
phy (PET-CT) with peritoneal, pulmonary, bone and
lymph nodes hypercaptation. 
We thus decided to switch treatment to lenalidomide
as administered in an ongoing phase 2 clinical trial,4 with
25 mg per day, 21 days out of 28. The patient experi-
enced grade 2 skin toxicity needing dose adjustments.
One month later, he suffered a pulmonary embolism
despite prophylaxis with aspirin and also presented a
progression of peritoneal disease and liver metastases,
hence lenalidomide treatment was also interrupted. Of
note, the only patient with histiocytic sarcoma included
in the above-mentioned trial also developed a deep
venous thrombosis.
During this time lapse, the patient’s daughter was diag-
nosed with BRCA1-related early breast cancer at 34 years
of age. After genetic counseling, the same hereditary
mutation in this base excision repair gene was detected in
our patient, which occurred after our paper was accepted
for publication. A DNA sequencing analysis on the tumor
found neither a biallelic mutation nor a loss of heterozy-
gosity (LOH), which could have indicated a hereditary
origin of this rare disease.  However, preclinical data did
suggest that BRCA1 haploinsufficiency may contribute to
genomic instability.5 To our knowledge, this is the first
reported case of histiocytic sarcoma in a BRCA1 carrier. 
The patient died in October 2017 from progressive dis-
ease with bowel obstruction, two months into his 7th
treatment line. His 20 months survival was unexpectedly
long according to recent epidemiologic data showing a
median overall survival of only six months for histiocytic
sarcomas.6
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